Cala Health, founded in 2014, is a pioneering bioelectronic medicine company aiming to revolutionize the management of chronic diseases. Headquartered in the San Francisco Bay Area, Cala Health leverages cutting-edge neuroscience and technology to create wearable neuromodulation therapies.
The company's flagship product targets essential tremor, a neurological condition impacting over seven million individuals, characterized by debilitating hand tremors. Cala Health's approach involves personalized peripheral nerve stimulation, setting a new paradigm in disease management.
With new therapies underway in neurology, cardiology, and psychiatry, Cala Health is expanding its scope within the Health Care and Hardware industries. In its latest funding round, Cala Health secured a significant $77.00M Series D investment on November 16, 2021, with backing from prominent investors such as Ascension Ventures, Dolby Ventures, Innovatus Capital Partners, and Peak 6. This investment positions the company favorably for future growth and product development.